NL-OMON36630已完成不适用
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy Volunteers - LY2623091 MAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy males and/or healthy females (postmenopausal/sterilized)
- •- 18-65 years, inclusive
- •- BMI: 19.0-32.5 kg/m2, inclusive
- •- non-smoking, or smoking a maximum of10 cigarettes/day
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects with Painful Lumbar Radiculopathylow back painPainful Lumbar Radiculopathy10041543NL-OMON40320Biogen Idec78
已完成
不适用
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral dosing in healthy subjects including brain Serotonin Transporter (SERT) occupancy by Positron Emission Tomography (PET).chronische pijn aan beschadigde organen.visceral painNL-OMON34068Eli Lilly51
已完成
不适用
Study of the Safety, Tolerability and Pharmacokinetics of LY2623091 after Single Oral Dosing in Healthy Subjectschronic kidney diseaseNL-OMON34283Chorus LRL (Division of Eli Lilly)18
已完成
不适用
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy ParticipantsNL-OMON50998Eli Lilly16
进行中（未招募）
1 期
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity.Weight managementMedDRA version: 20.0Level: HLTClassification code 10027428Term: Metabolic disorders NECSystem Organ Class: 100000004861EUCTR2024-000081-22-Outside-EU/EEAEli Lilly and Company